Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,384 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combinations of olmesartan and a calcium channel blocker or a diuretic in elderly hypertensive patients: a randomized, controlled trial.
Ogihara T, Saruta T, Rakugi H, Saito I, Shimamoto K, Matsuoka H, Shimada K, Ito S, Horiuchi M, Imaizumi T, Takishita S, Higaki J, Katayama S, Kimura G, Umemura S, Ura N, Hayashi K, Odawara M, Tanahashi N, Ishimitsu T, Kashihara N, Morita S, Teramukai S; COLM Investigators. Ogihara T, et al. Among authors: katayama s. J Hypertens. 2014 Oct;32(10):2054-63; discussiom 2063. doi: 10.1097/HJH.0000000000000281. J Hypertens. 2014. PMID: 24999799 Free PMC article. Clinical Trial.
Rationale, study design and implementation of the COLM study: the combination of OLMesartan and calcium channel blocker or diuretic in high-risk elderly hypertensive patients.
Ogihara T, Saruta T, Rakugi H, Shimamoto K, Ito S, Matsuoka H, Horiuchi M, Imaizumi T, Takishita S, Higaki J, Katayama S, Saito I, Shimada K; COLM study investigators. Ogihara T, et al. Among authors: katayama s. Hypertens Res. 2009 Feb;32(2):163-7. doi: 10.1038/hr.2008.31. Epub 2009 Jan 23. Hypertens Res. 2009. PMID: 19262477 Clinical Trial.
Preferable effects of olmesartan/calcium channel blocker to olmesartan/diuretic on blood pressure variability in very elderly hypertension: COLM study subanalysis.
Rakugi H, Ogihara T, Saruta T, Kawai T, Saito I, Teramukai S, Shimada K, Katayama S, Higaki J, Odawara M, Tanahashi N, Kimura G; COLM Investigators. Rakugi H, et al. Among authors: katayama s. J Hypertens. 2015 Oct;33(10):2165-72. doi: 10.1097/HJH.0000000000000668. J Hypertens. 2015. PMID: 26066644 Free PMC article. Clinical Trial.
Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study.
Makino H, Haneda M, Babazono T, Moriya T, Ito S, Iwamoto Y, Kawamori R, Takeuchi M, Katayama S; INNOVATION Study Group. Makino H, et al. Among authors: katayama s. Hypertens Res. 2008 Apr;31(4):657-64. doi: 10.1291/hypres.31.657. Hypertens Res. 2008. PMID: 18633177 Clinical Trial.
In half of hypertensive diabetics, co-administration of a calcium channel blocker and an angiotensin-converting enzyme inhibitor achieved a target blood pressure of <130/80 mmHg: the azelnidipine and temocapril in hypertensive patients with type 2 diabetes (ATTEST) study.
Katayama S, Kawamori R, Iwamoto Y, Saito I, Kuramoto K; ATTEST Study Group. Katayama S, et al. Hypertens Res. 2008 Aug;31(8):1499-508. doi: 10.1291/hypres.31.1499. Hypertens Res. 2008. PMID: 18971523 Clinical Trial.
Guidelines for treatment of hypertension in the elderly--2002 revised version.
Ogihara T, Hiwada K, Morimoto S, Matsuoka H, Matsumoto M, Takishita S, Shimamoto K, Shimada K, Abe I, Ouchi Y, Tsukiyama H, Katayama S, Imai Y, Suzuki H, Kohara K, Okaishi K, Mikami H. Ogihara T, et al. Among authors: katayama s. Hypertens Res. 2003 Jan;26(1):1-36. doi: 10.1291/hypres.26.1. Hypertens Res. 2003. PMID: 12661910 Free article. Review. No abstract available.
Preventing microalbuminuria in patients with diabetes: rationale and design of the Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study.
Haller H, Viberti GC, Mimran A, Remuzzi G, Rabelink AJ, Ritz E, Rump LC, Ruilope LM, Katayama S, Ito S, Izzo JL Jr, Januszewicz A. Haller H, et al. Among authors: katayama s. J Hypertens. 2006 Feb;24(2):403-8. doi: 10.1097/01.hjh.0000202820.56201.e6. J Hypertens. 2006. PMID: 16508590 Clinical Trial.
1,384 results